DGAP-News

Immunic AG: Immunic successfully closes 17.5 million Euro Series A financing round (news with additional features)

DGAP-News: Immunic AG / Key word(s): Financing
Immunic AG: Immunic successfully closes 17.5 million Euro Series A financing
round (news with additional features)

27.09.2016 / 07:38
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Immunic successfully closes 17.5 million Euro Series A financing round

- One of the largest Series A biotech venture capital financings in
Germany

- Venture capital consortium led by renowned sector investors Life
Sciences Partners (LSP) and LifeCare Partners (LCP)

- Immunic focuses on the development of small molecule immune modulators
up to clinical proof of concept

Planegg-Martinsried, Germany, September 27, 2016 - Immunic AG (Immunic), a
recently formed private start-up biotech company in Planegg-Martinsried
near Munich, Germany, today announced that it has closed its Series A
financing round totaling EUR 17.5 million of preferred stock financing. The
financing round was led by Life Sciences Partners V Coöperatief U.A. (LSP,
The Netherlands) and LifeCare Partners (LCP, Switzerland). Further
participating investors were Bayern Kapital (Landshut, Germany), High-Tech
Gründerfonds (HTGF, Bonn, Germany) and additional private investors.

Immunic was founded in April 2016 with the purpose to advance promising
drug development projects to clinical proof-of-concept. The focus of
Immunic is the development of orally available, small molecule immune
modulators to treat immune and autoimmune diseases such as inflammatory
bowel disease (IBD) or psoriasis.

Dr. Manfred Gröppel, Immunic's co-founder and Chief Operating Officer,
says: "This financing is an important validation of the Immunic team. We
are excited to have convinced a renowned group of professional investors.
Their commitment to provide substantial start-up financing to our venture
and their expertise in shaping successful biotech companies will allow us
to boost our development activities."

Dr. Andreas Mühler, Immunic's co-founder and Chief Medical Officer, adds:
"The funds provided enable us to start developing convenient yet powerful
new therapies for patients that suffer from debilitating diseases caused by
the immune system."

"There are still large unmet medical needs in the field of autoimmune and
immunological diseases. This is particularly true for safe and convenient
therapies that can be taken as a tablet, a dosage form preferred over
intravenous administration by patients and health care systems alike",
states Dr. Jörg Neermann, partner at LSP and member of Immunic's
Supervisory Board. "We are convinced that Immunic's experienced management